212 related articles for article (PubMed ID: 34391888)
1. Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples.
Klaeger S; Apffel A; Clauser KR; Sarkizova S; Oliveira G; Rachimi S; Le PM; Tarren A; Chea V; Abelin JG; Braun DA; Ott PA; Keshishian H; Hacohen N; Keskin DB; Wu CJ; Carr SA
Mol Cell Proteomics; 2021; 20():100133. PubMed ID: 34391888
[TBL] [Abstract][Full Text] [Related]
2. Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry.
Phulphagar KM; Ctortecka C; Jacome ASV; Klaeger S; Verzani EK; Hernandez GM; Udeshi ND; Clauser KR; Abelin JG; Carr SA
Mol Cell Proteomics; 2023 Jun; 22(6):100563. PubMed ID: 37142057
[TBL] [Abstract][Full Text] [Related]
3. Sensitive, high-throughput HLA-I and HLA-II immunopeptidomics using parallel accumulation-serial fragmentation mass spectrometry.
Phulphagar KM; Ctortecka C; Vaca Jacome AS; Klaeger S; Verzani EK; Hernandez GM; Udeshi N; Clauser K; Abelin J; Carr SA
bioRxiv; 2023 Mar; ():. PubMed ID: 36993564
[TBL] [Abstract][Full Text] [Related]
4. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations.
Minegishi Y; Kiyotani K; Nemoto K; Inoue Y; Haga Y; Fujii R; Saichi N; Nagayama S; Ueda K
Commun Biol; 2022 Aug; 5(1):831. PubMed ID: 35982173
[TBL] [Abstract][Full Text] [Related]
5. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
6. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.
Ghosh M; Gauger M; Marcu A; Nelde A; Denk M; Schuster H; Rammensee HG; Stevanović S
Mol Cell Proteomics; 2020 Mar; 19(3):432-443. PubMed ID: 31937595
[TBL] [Abstract][Full Text] [Related]
7. Benchmarking Bioinformatics Pipelines in Data-Independent Acquisition Mass Spectrometry for Immunopeptidomics.
Shahbazy M; Ramarathinam SH; Illing PT; Jappe EC; Faridi P; Croft NP; Purcell AW
Mol Cell Proteomics; 2023 Apr; 22(4):100515. PubMed ID: 36796644
[TBL] [Abstract][Full Text] [Related]
8. TOF
Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
[TBL] [Abstract][Full Text] [Related]
9. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
[TBL] [Abstract][Full Text] [Related]
10. A microcapillary column switching HPLC-electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules.
van der Heeft E; ten Hove GJ; Herberts CA; Meiring HD; van Els CA; de Jong AP
Anal Chem; 1998 Sep; 70(18):3742-51. PubMed ID: 9751018
[TBL] [Abstract][Full Text] [Related]
11. Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.
Pak H; Michaux J; Huber F; Chong C; Stevenson BJ; Müller M; Coukos G; Bassani-Sternberg M
Mol Cell Proteomics; 2021; 20():100080. PubMed ID: 33845167
[TBL] [Abstract][Full Text] [Related]
12. In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies.
Pandey K; Mifsud NA; Lim Kam Sian TCC; Ayala R; Ternette N; Ramarathinam SH; Purcell AW
Mol Immunol; 2020 Jul; 123():7-17. PubMed ID: 32387766
[TBL] [Abstract][Full Text] [Related]
13. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Bassani-Sternberg M
Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
[TBL] [Abstract][Full Text] [Related]
14. A Novel Differential Ion Mobility Device Expands the Depth of Proteome Coverage and the Sensitivity of Multiplex Proteomic Measurements.
Pfammatter S; Bonneil E; McManus FP; Prasad S; Bailey DJ; Belford M; Dunyach JJ; Thibault P
Mol Cell Proteomics; 2018 Oct; 17(10):2051-2067. PubMed ID: 30007914
[TBL] [Abstract][Full Text] [Related]
15. Accurate Quantitative Proteomic Analyses Using Metabolic Labeling and High Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS).
Pfammatter S; Bonneil E; McManus FP; Thibault P
J Proteome Res; 2019 May; 18(5):2129-2138. PubMed ID: 30919622
[TBL] [Abstract][Full Text] [Related]
16. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Front Immunol; 2017; 8():1367. PubMed ID: 29104575
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
18. Deep Learning-Assisted Analysis of Immunopeptidomics Data.
Gabriel W; Picciani M; The M; Wilhelm M
Methods Mol Biol; 2024; 2758():457-483. PubMed ID: 38549030
[TBL] [Abstract][Full Text] [Related]
19. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method.
Flad T; Spengler B; Kalbacher H; Brossart P; Baier D; Kaufmann R; Bold P; Metzger S; Blüggel M; Meyer HE; Kurz B; Müller CA
Cancer Res; 1998 Dec; 58(24):5803-11. PubMed ID: 9865739
[TBL] [Abstract][Full Text] [Related]
20. The impact of immunopeptidomics: From basic research to clinical implementation.
Shapiro IE; Bassani-Sternberg M
Semin Immunol; 2023 Mar; 66():101727. PubMed ID: 36764021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
